{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-050592","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2021-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.675726+00:00","generated_at":"2026-06-29T00:45:38.729334+00:00","sec_items":["1.01","2.01","9.01","5.02","3.02","4.01","5.01","5.06","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amplitude Healthcare completes business combination with Jasper Therapeutics; begins trading as JSPR","bullets":["Redemption of 9,262,099 AMHC shares for $92.7M; PIPE of $100M from 10M shares at $10.00 each.","Old Jasper equity valued at $275M; post-closing shares: 36.5M voting, 1.3M non-voting, 2.7M options.","Sponsor deposited 1,050,000 earnout shares subject to price thresholds of $11.50, $15, $18 VWAP.","New company renamed Jasper Therapeutics, Inc.; tickers JSPR (common) and JSPRW (warrants) on Nasdaq.","Amended registration rights agreement with 180-day lock-up; indemnification agreements with directors/officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-050592","json":"https://secwatch.observer/filing/0001213900-21-050592.json","markdown":"https://secwatch.observer/filing/0001213900-21-050592.md","text":"https://secwatch.observer/filing/0001213900-21-050592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:45:38.729334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"100eef0ea8","claim":"Vishal Kapoor departed as Executive Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"2946fbddf6","claim":"Bala Venkataraman departed as Executive Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"67c08698b7","claim":"Kenneth Clifford departed as Executive Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b77754c67b","claim":"William Lis was appointed as President, Chief Executive Officer and Executive Chairman at Jasper Therapeutics, Inc..","evidence_excerpt":"William Lis President, Chief Executive Officer and Executive Chairman of the New Jasper Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Chief Executive Officer and Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"d885d49bc7","claim":"Kevin N. Heller, M.D. was appointed as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..","evidence_excerpt":"Kevin N. Heller, M.D. Executive Vice President, Research and Development","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Research and Development"}],"fact_type":"executive_change"},{"claim_id":"d9e3135e82","claim":"Jeet Mahal was appointed as Chief Financial and Business Officer and Corporate Secretary at Jasper Therapeutics, Inc..","evidence_excerpt":"Jeet Mahal Chief Financial and Business Officer and Corporate Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/0001213900-21-050592-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial and Business Officer and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}